TNFRSF10B and neoplasm: The low FADD protein expression in most HPV(+) cells supports this hypothesis (Fig. 3A), which could explain why TRAIL or anti-TRAILR2/DR5 alone had minimal inhibitory effects on HPV(+) tumor cells (Figs. 4, 5).